crossing96/oncoscreening huggingface dataset:
Evaluation of the efficacy and safety of salvage photodynamic therapy with talaporfin sodium for lesions beyond those indicated for investigator-initiated clinical trials.	OBJECTIVES: Since the efficacy of salvage photodynamic therapy (PDT) for locally recurrent esophageal cancer after definitive chemoradiotherapy (CRT) was proven for the first time in an investigator-initiated clinical trial, various reports have supported the clinical utility of PDT for these lesions. However, the clinical trial had limited indications, including a luminal circumference of ≤1/2, maximum longitudinal lesion length of 3 cm, and no invasion into the cervical esophagus, and there have been few reports of treatment outcomes for lesions exceeding the indications used in the investigator-initiated clinical trial. Therefore, this study was performed to assess the outcomes of treating lesions exceeding the above indications. METHODS: We retrospectively enrolled 34 consecutive esophageal cancer patients with 38 lesions who underwent PDT with talaporfin sodium. Lesions were classified as meeting (within-indications group; 23 patients, 25 lesions) or exceeding (beyond-indications group; 11 patients, 13 lesions) the indications in the investigator-initiated clinical trial. The local complete response rate (L-CR), overall survival (OS), progression-free survival (PFS), and incidence of PDT-related adverse events were compared between the groups. RESULTS: The L-CR rate was 88.0 and 92.3% in the within- and beyond-indications groups, respectively. The 2-year OS rate was 69.5% and 90.0% and the 2-year PFS rate was 43.3 and 56.6% in the within- and beyond-indications groups, respectively. In terms of adverse events, there were no serious adverse events in either group. CONCLUSION: Salvage PDT might be effective for local recurrence after CRT for lesions exceeding the indications in the investigator-initiated clinical trial.	esophagus
Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma.	"BACKGROUND: While the development in multimodal therapies has helped improve treatment outcomes for patients with locally advanced gastric adenocarcinoma (LAGC), there still exist disparities in opinion with an optimal treatment plan. This consensus hopes to provide clinicians with structured guidelines to aid in the decision-making for treatment options for LAGC. METHODS: The consensus statement was initiated by establishing a taskforce in collaboration with the Asia Pacific Gastroesophageal Cancer Congress (APGCC) and a multidisciplinary expert panel was selected. Clinical questions on LAGC where perceived variance in practice or opinion may exist were formulated. Studies involving patients with Stage 2 or 3 gastric or Siewert 3 junctional cancers with treatment arms of perioperative chemotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy, immunotherapy and surgery were included. A total of two rounds of voting were performed. Consensus was determined to be reached when a single answer or a combination of either ""strongly agree/agree"" or ""strongly disagree/disagree"" responses exceeded 75%. RESULTS: A total of thirteen clinical questions were developed. They were identified through five main categories: Distal LAGC, Proximal LAGC, Deficient mismatch repair tumors, Chemotherapy and Immunotherapy, and Elderly/Unfit patients. After two rounds of voting by our multidisciplinary expert panel, eleven out of a total thirteen clinical questions had reached consensus. No consensus was reached for two clinical questions. CONCLUSION: The APGCC consensus statement aims to guide clinicians in the treatment options for LAGC and Siewert 3 junctional cancer and has clarified some of the roles of perioperative chemotherapy and immunotherapy."	esophagus
Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation.	Esophageal squamous cell carcinoma (ESCC) remains a lethal malignancy with limited therapeutic options. This study investigated the antitumor efficacy and mechanisms of decursin, a natural pyranocoumarin derivative, against ESCC. In vitro analyses demonstrated that decursin selectively inhibited ESCC cell viability (IC50: 14.62 ± 0.61-26.20 ± 2.11 μM across TE-1, KYSE-30, and KYSE-150 cell lines) without affecting normal esophageal epithelial cells (Het-1A). Decursin (10 μM) suppressed colony formation, impaired wound healing (p < 0.001 at 48 h), and reduced Transwell migration/invasion in KYSE-150 cells. Subcutaneous xenograft models revealed significant tumor growth inhibition (p < 0.01) with decursin treatment (10 mg/kg, intraperitoneal), accompanied by no systemic toxicity. Mechanistically, decursin induced G0/G1 cell cycle deceleration (p < 0.01) and apoptosis through ubiquitin-proteasome-mediated degradation of oncoproteins TP63 and SOX2. Time- and dose-dependent protein suppression was reversed by proteasome inhibitor MG-132, but unaffected by lysosomal inhibition. These findings establish decursin as a promising therapeutic agent for ESCC, functioning via proteasomal degradation of key oncogenic drivers, and provide a rationale for decursin's further development as a targeted monotherapy or chemosensitizer in multimodal regimens.	esophagus
Changes in Esophageal Cancer Survival: A Global Review of Survival Analysis from Cancer Registration Data over the Past Three Decades.	OBJECTIVE: To describe survival trends and global patterns of esophageal cancer (EC) using survival data from population-based cancer registries. METHODS: We systematically searched PubMed, EMBASE, Web of Science, SEER, and SinoMed databases for articles published up to 31 December 2023. Eligible EC survival estimates were evaluated according to country or region, period, sex, age group, pathology, and disease stage. RESULTS: After 2010, Jordan exhibited the highest age-standardized 5-year relative survival rates (RSRs)/net survival rates (NSRs) at 41.1% between 2010 and 2014, while India had the lowest, at 4.1%. Survival rates generally improved with diagnostic age across most countries, with significant increases in South Korea and China, of 12.7% and 10.5% between 2000 and 2017, respectively. Survival was higher among women compared to men, ranging from 0.4%-10.9%. Survival rates for adenocarcinoma and squamous cell carcinoma were similar, differing by about 4%. In China, the highest age-standardized RSRs/NSRs was 33.4% between 2015 and 2017. Meanwhile, the lowest was 5.3%, in Qidong (Jiangsu province) between 1992-1996. CONCLUSION: Global EC survival rates have improved significantly in recent decades, but substantial geographical, sex, and age disparities still exist. In Asia, squamous cell carcinoma demonstrated superior survival rates compared to adenocarcinoma, while the opposite trend was observed in Western countries. Future research should clarify the prognostic factors influencing EC survival and tailor prevention and screening strategies to the changing EC survival patterns.	esophagus
Hsa_circ_0049271 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance by Enhancing Cellular Senescence via miR-455-5p/ETS1.	Cisplatin resistance is a major therapeutic challenge in esophageal squamous cell carcinoma (ESCC). circRNAs play an important role in cisplatin resistance. The aim of this paper was to investigate the role and mechanism of hsa_circ_0049271 in ESCC progression and drug resistance. GEO database was retrieved to collect circRNAs, miRNAs, and mRNAs associated with cisplatin resistance in ESCC. Reverse transcription-quantitative PCR (RT-qPCR) was used to detect hsa_circ_0049271 expression levels in ESCC cell lines. CCK-8 assay, flow cytometric assay, and cell migration/invasion assays were used to examine the function of hsa_circ_0049271 in ESCC cells. RT-qPCR and coculture assays were used to detect the effect of circRNA_103615 on cellular senescence under cisplatin treatment. Hsa_circ_0049271, miR-455-5p, and ETS1 were dysregulated in ESCC tissues. ESCC cell lines had increased levels of hsa_circ_0049271 and ETS1 mRNA compared with normal cells and normal tissues, as well as decreased levels of miR-455-5p. Functionally, small interfering RNA silencing of hsa_circ_0049271 by small interfering RNA resulted in suppression of cell growth, migration, and invasion in both non-senescent and senescent cells. MiR-455-5p was significantly increased, but ETS1 expression was significantly decreased after hsa_circ_0049271 knockdown. Hsa_circ_0049271 promoted the secretion of senescence-associated secretory phenotypes, including IL1B, IL6, CXCL5, and MMP3. Hsa_circ_0049271 may enhance DDP treatment-induced cellular senescence to promote ESCC progression and chemoresistance through the miR-455-5p/ETS1 axis.	esophagus
PTGDS deficiency as a driver of M2 macrophage polarization and immunosuppressive microenvironment in esophageal squamous cell carcinoma: an experimental study.	INTRODUCTION: Esophageal squamous cell carcinoma (ESCC) exhibits poor survival linked to M2 macrophage-polarized microenvironment. This study aimed to elucidate the role of prostaglandin D2 synthase (PTGDS) in modulating tumor microenvironment (TME) and its prognostic implications in ESCC. MATERIALS AND METHODS: Transcriptomic datasets (GSE53624, GSE121931) were analyzed using immune deconvolution and weighted gene co-expression network analysis to identify genes associated with M2 macrophage infiltration. Differentially expressed genes between tumor and normal tissues were assessed in Gaozhou-RNA cohort. Cox regression analyses were conducted to evaluate prognostic factors. A nomogram incorporating PTGDS expression and clinicopathological parameters was developed and validated by immunohistochemistry (IHC) which was performed in the Gaozhou-IHC cohort. In vitro experiments were used to validate the role of PTGDS. RESULTS: PTGDS expression was significantly downregulated in ESCC tissues and reduced PTGDS expression was identified as a significantly prognostic factor for worse overall survival (OS). A combined nomogram demonstrated strong predictive accuracy, with area under the curve (AUC) values of 0.63, 0.77, and 0.83 for 1-, 3-, and 5-year OS predictions in the GSE53624 cohort, which remained consistent across validation cohorts (GSE121931 and Gaozhou-IHC cohort). Lower PTGDS expression was significantly associated with increased myeloid-derived suppressor cells recruitment, reduced T cell infiltration, and impaired T cell cytotoxicity. IHC confirmed elevated CD206 + M2 macrophage infiltration in PTGDS-low tumors. In vivo and in vitro experiments further demonstrated PTGDS overexpression effectively suppressed M2 macrophage polarization. CONCLUSION: PTGDS deficiency promotes immunosuppressive TME remodeling and predicts unfavorable clinical outcomes in ESCC, which might be a potential prognostic biomarker in ESCC.	esophagus
Characterization of subepithelial tumors of upper gastrointestinal tract by endoscopic ultrasound.	In this article we comment on the paper by Xu et al describing retrospective data on endoscopic treatment outcome of esophageal gastrointestinal stromal tumors (GISTs). Esophageal GIST is a rare type of mesenchymal tumor. GISTs originate from the interstitial cells of Cajal, which are pacemaker cells involved in gut motility. GISTs are most commonly found in the stomach and small intestine, but esophageal involvement is rare. Esophageal GISTs account for < 1% of all GISTs. Endoscopic resection remains the mainstay for small, localized tumors with excellent outcomes. However, larger tumors may require multidisciplinary strategies to provide the best oncological outcomes. Here, we discuss the usefulness of endoscopic ultrasound (EUS) of subepithelial tumors of the upper gastrointestinal tract. EUS is a crucial tool in the diagnosis, staging, and management of subepithelial masses. Given the subepithelial nature of these tumors, standard endoscopy is not adequate, making EUS essential for a comprehensive assessment. EUS provides accurate tumor size assessment and enables fine needle aspirations guided biopsy, for treatment planning.	esophagus
Application of deep learning models in the pathological classification and staging of esophageal cancer: A focus on Wave-Vision Transformer.	BACKGROUND: Esophageal cancer is the sixth most common cancer worldwide, with a high mortality rate. Early prognosis of esophageal abnormalities can improve patient survival rates. The progression of esophageal cancer follows a sequence from esophagitis to non-dysplastic Barrett's esophagus, dysplastic Barrett's esophagus, and eventually esophageal adenocarcinoma (EAC). This study explored the application of deep learning technology in the precise diagnosis of pathological classification and staging of EAC to enhance diagnostic accuracy and efficiency. AIM: To explore the application of deep learning models, particularly Wave-Vision Transformer (Wave-ViT), in the pathological classification and staging of esophageal cancer to enhance diagnostic accuracy and efficiency. METHODS: We applied several deep learning models, including multi-layer perceptron, residual network, transformer, and Wave-ViT, to a dataset of clinically validated esophageal pathology images. The models were trained to identify pathological features and assist in the classification and staging of different stages of esophageal cancer. The models were compared based on accuracy, computational complexity, and efficiency. RESULTS: The Wave-ViT model demonstrated the highest accuracy at 88.97%, surpassing the transformer (87.65%), residual network (85.44%), and multi-layer perceptron (81.17%). Additionally, Wave-ViT exhibited low computational complexity with significantly reduced parameter size, making it highly efficient for real-time clinical applications. CONCLUSION: Deep learning technology, particularly the Frequency-Domain Transformer model, shows promise in improving the precision of pathological classification and staging of EAC. The application of the Frequency-Domain Transformer model enhances the automation of the diagnostic process and may support early detection and treatment of EAC. Future research may further explore the potential of this model in broader medical image analysis applications, particularly in the field of precision medicine.	esophagus
PC4 Potentially Predicts Chemoradiation-Induced Antitumor Immunity in Esophageal Squamous Cell Carcinoma.	Chemoradiotherapy (CRT) induces an antitumor immune response in esophageal squamous cell carcinoma (ESCC), and thereby has enormous potential by itself and in combination with immune checkpoint inhibitors (ICI). Our previous studies indicated that human positive cofactor 4 (PC4) was an independent predictor of poor survival in patients with ESCC or lung cancer who were treated with definitive chemoradiation, with a mechanism involving the enhancement of nonhomologous end joining (NHEJ)-mediated DNA repair. Due to the important role of double-strand DNA (dsDNA) in the antitumor immune response, the present study aims to investigate PC4 as a predictor of pathological response and antitumor immune response in ESCC patients who underwent neoadjuvant CRT. In ESCC, low PC4 expression levels have significant power to predict pCR. In particular, pCR is 61.2% in patients with low PC4 expression, but only 23.4% in patients with high PC4. Both disease-free survival (DFS) and overall survival (OS) are significantly longer for patients with low PC4 than for those with high PC4. In agreement with our previous finding that PC4 participates in NHEJ-mediated DNA repair, our further analysis indicates that the expression of PC4 is not only significantly negatively correlated with cyto-free dsDNA in postoperative specimens, but also with tumor-infiltrating CD8(+)T lymphocytes (CD8(+)TILs) and GZMB(+)CD8(+)TILs, suggesting a possible mechanism that high PC4 negatively regulates the antitumor response and therefore results in poor prognosis. Together, our findings demonstrate that low expression of PC4 is a potential biomarker for predicting the antitumor immune response to chemoradiation in patients with operable locally advanced ESCC.	esophagus
Association Between Preoperative Diaphragm Thickening Fraction and Postoperative Pulmonary Complications Following Thoracoscopic Esophagectomy.	Background: This study aimed to investigate the association between preoperative diaphragm thickening assessed using ultrasound imaging and postoperative pulmonary complications (PPCs) in patients undergoing thoracoscopic esophagectomy for esophageal cancer. Methods: This single-center, prospective, cohort study enrolled subjects with esophageal cancer who were scheduled to undergo thoracoscopic esophagectomy between June 2021 and May 2024. The diaphragm thickening fraction (DTF) was measured using ultrasound imaging preoperatively and 1 and 2 weeks postoperatively. Our primary outcome comprised overall PPCs. We investigated the longitudinal change in the DTF and the relationship between the DTF and PPCs. We also examined the optimal cutoff value for the ability of the DTF to predict PPCs. Results: This study enrolled 73 subjects. PPCs occurred in 21 (29%) subjects, 10 (14%) of whom had pneumonia. The estimated difference between the preoperative and 1-week postoperative least squares means of the DTF was -56.3% (95% credible interval [CrI] -65.4, -47.2), and -36.5% (95% CrI: -43.7, -29.2) between the preoperative and 2-week postoperative values. The mean relative risk of preoperative DTF to PPCs was 0.89 per 10% increase (95% CrI: 0.80, 0.99), after adjusting for potential confounders. In the posterior distribution, the probability that the RR of the DTF per 10% increase would be <1 was 98.0%. According to the receiver operating characteristic curve, the optimal cutoff value of preoperative DTF predicting PPCs was 123.6%. Conclusions: DTF is decreased 1 and 2 weeks after thoracoscopic esophagectomy in subjects with esophageal cancer. The higher the preoperative DTF, the lower the risk of occurrence of PPCs.	esophagus
Predictors of overall survival in esophageal cancer patients with pathologic complete response after neoadjuvant therapy and surgery.	Esophageal cancer recurrence occurs even in those who have a pathologic complete response (pCR) following neoadjuvant therapy and esophagectomy. The purpose of this study is to identify predictors of overall survival in patients with pCR. Using the National Cancer Database, a retrospective analysis of all adult patients with ypT0N0 esophageal cancer following neoadjuvant chemotherapy and radiation between 2012 and 2020 was performed. The variables analyzed were age, gender, ethnicity, insurance, Charlson-Deyo comorbidity score, clinical stage, and facility type. Cox proportional hazards regression was used to identify predictors of overall survival. Wilcoxon rank sum and chi-square tests were used for continuous and categorical variables, respectively, with a significance level of P < 0.05. There were 2767 patients that met the inclusion criteria, with the mean age of 63; 78% were male and 92% were White. Median survival was 6.6 years (95% confidence interval [CI]: 6.21-7.12). In multivariable analysis, older age (hazard ratio [HR] 2.7 per year, P < 0.0001), male gender (HR 3.3, P = 0.02), Charlson-Deyo score ≥ 2 (HR 3.9, P = 0.01), and advanced clinical stage (Stage IV vs. Stage I, HR 21.93, P < 0.001) predicted worse overall survival. Among patients who achieved pCR, advanced age, male gender, comorbidities, and clinical stage significantly influenced survival. Tumor- and treatment-related factors that impacted overall survival are advanced clinical stage and treatment at community facilities. These findings suggest that patients with advanced-stage esophageal cancer who achieve pCR remain at higher risk for recurrence and future studies should investigate this population further.	esophagus
Different Appearances of Esophageal Squamous Cell Carcinoma in 18 F-PSMA PET/CT Versus 18 F-FDG PET/CT.	An 81-year-old man with a history of prostate cancer, status post radiation therapy, was referred for a prostate-specific membrane antigen (PSMA) PET/CT scan. Fluorine-18 DCF-Pyl (Pylarify) PSMA PET/CT showed focal increased radiotracer uptake at the right prostate and bilateral iliac chain metastatic lymph nodes. The same PSMA PET/CT showed focal increased radiotracer uptake at the junction of the mid to lower esophagus. 18 F-FDG PET/CT identified a large hypermetabolic esophageal mass in the mid to lower esophagus, showing a greater extent of esophageal disease than the PSMA PET/CT. An endoscopic biopsy confirmed poorly differentiated esophageal squamous cell carcinoma.	esophagus
Expression of kinetochore component NDC80 promotes esophageal squamous cell carcinoma cells proliferation and migration.	"BACKGROUND: NDC80, a crucial component of the kinetochore, plays a pivotal role in regulating cell mitosis. Recent studies reported that NDC80 regulates the proliferation of cancer cells and may be related to poor prognosis in cancer. However, the biological function and mechanism of NDC80 in esophageal squamous cell carcinoma (ESCC) have not yet been elucidated. In this study, we analyzed the expression and mutation of NDC80 in ESCC tissue and assessed its impact on ESCC cells in vitro. METHODS: A total of 52 ESCC tissues samples were collected and NDC80 gene status was analyzed by whole exome sequence. shRNA was used to knockdown NDC80 expression in two ESCC cell lines TE1 and ECA109 by targeting silence NDC80 gene. Cellular proliferation, apoptosis, migration, and invasion were examined. RESULTS: Copy number variants (CNVs) of NDC80 were detected in 40.4% (21/52) cancer tissues. Genes with local CNVs values greater than 0.3 were classified as ""gain"". 23.1% (12/52) of cases showed CNVs gain and 58.3% (7/12) of which with genotype of AAB. Compared with patients of other NDC80 CNVs status, CNVs gain patients had relatively shorter overall survival, however with no statistic difference (19.9 ± 0.8 months vs. 30.9 ± 5.1 months, p = 0.124). Single nucleotide polymorphism mutation of NDC80 was detected in only 5.8% (3/52) cancer tissues including two previous reported mutation rs2271754 and rs6506019, and one novel SNP of C/A-T/G in 2,577,492, GRCh38.p13 intron variant in one case. The knockdown of NDC80 in vitro assays significantly suppressed cellular proliferation and induced increased apoptosis in both TE1 and ECA109 cells. Furthermore, the migration and invasion ability of both TE1 and ECA109 cells were also attenuated upon knockdown of NDC80. CONCLUSION: CNVs were identified as the predominant genetic variation of NDC80 gene in ESCC patients. In vitro assays suggested that NDC80 was not only involved into proliferation and apoptosis but also migration and invasion of ESCC cells."	esophagus